Company Financials
Acceleron Pharma Inc. Financials
United States dollar
business
Acceleron Pharma Inc. Company Profile
Main Stock Listing
NASDAQ: XLRN
Market Capitalization $10.56 Billion as of Nov. 1, 2021
Market Cap History
Valuations Metrics as of Jan. 25, 2025
| Trailing PE | -61.22 |
| Forward PE | -54.17 |
| Price to Sales TTM | $118.15 |
| Price to Book MRQ | $15.78 |
| Enterprise to Revenue | 111.16 |
| Enterprise to EBITDA | -62.92 |
Financial Reports as of Sep. 30, 2021
Financials
| Fiscal Year Ends | 2020-12-31 |
| Most Recent Quarter | 2021-09-30 |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets TTM | -18.18% |
| Return on Equity TTM | 18.92% |
Income Statement
| Revenue TTM | $92,523,000 |
| Revenue per Share TTM | $1.63 |
| Quarterly Revenue Growth | 22.40% |
| Gross Profit TTM | $-81,394,000 |
| EBITDA | $None |
| Net Income to Common TTM | $-166,030,000 |
| Diluted EPS TTM | $-2.92 |
| Quarterly Earnings Growth YoY | % |
Balance Sheet
| Total Cash MRQ | $None |
| Total Cash per Share MRQ | $ |
| Total Debt MRQ | $ |
| Total Debt to Equity MRQ | -0.02 |
| Current Ratio MRQ | 47.16 |
| Book Value per Share MRQ | $-17.64 |
Cash Flow
| Operating Cash Flow TTM | $-142,664,000 |
| Levered Free Cash Flow TTM | $-166,030,000 |
XLRN Stock Info as of Jan. 25, 2025
Stock Statistics
| Shares Outstanding | 56,800,000 |
| Float Shares | None |
| Avg 10 Volume | 1,231,099 |
| Avg 30 Volume | None |
| Shares Short | None |
| Short Ratio | |
| Short % of Shares | % |
| % Held by Insiders | % |
| % Held by Institutions | % |
Stock Price Summary
| Beta | |
| Fifty Two Week Low | $111.75 |
| Fifty Two Week High | $189.99 |
| Fifty Two Week Change | % |
| Day 50 MA | $169.49 |
| Day 200 MA | $137.95 |
Dividends and Splits
| Forward Annual Dividend Rate | $ |
| Forward Annual Dividend Yield | % |
| Trailing Annual Dividend Rate | $ |
| Trailing Annual Dividend Yield | % |
| Payout Ratio | % |
| Dividend Date | |
| Ex Dividend Date | |
| Last Split Factor | |
| Last Split Date |